Raymond James Financial Inc. Invests $2.21 Million in Guardant Health, Inc. (NASDAQ:GH)

Raymond James Financial Inc. purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 72,364 shares of the company’s stock, valued at approximately $2,211,000. Raymond James Financial Inc. owned about 0.06% of Guardant Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of GH. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Guardant Health by 6.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock valued at $665,000 after buying an additional 1,844 shares during the period. Verition Fund Management LLC boosted its stake in Guardant Health by 220.6% in the third quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock valued at $863,000 after acquiring an additional 25,900 shares during the period. Erste Asset Management GmbH bought a new position in shares of Guardant Health during the third quarter valued at approximately $21,389,000. Janus Henderson Group PLC grew its holdings in shares of Guardant Health by 16.2% during the third quarter. Janus Henderson Group PLC now owns 60,578 shares of the company’s stock valued at $1,390,000 after purchasing an additional 8,432 shares during the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Guardant Health by 52.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock worth $27,007,000 after purchasing an additional 406,500 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 4.5 %

GH stock opened at $43.14 on Monday. The stock has a market capitalization of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. The firm has a 50-day moving average price of $44.66 and a 200-day moving average price of $34.37. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Raymond James reaffirmed an “outperform” rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Stifel Nicolaus upped their price target on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler raised their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Guggenheim restated a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Finally, Stephens reiterated an “overweight” rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.